Medical Information

Enzalutamide, as an anti prostate cancer drug, should focus on epilepsy risk, fatigue management, and drug interactions. The following provides a detailed explanation of the precautions from three aspects, strictly following medical evidence and medication standards.

Precautions for epilepsy risk

1. Basic risk assessment

Patients with a history of epilepsy should use it with caution, as enzalutamide may lower the seizure threshold. A neurological assessment should be conducted before treatment.

2. Inducing factor control

Avoid the simultaneous use of other drugs that lower the threshold for epilepsy, such as fluoroquinolone antibiotics, tricyclic antidepressants, etc.

3. Emergency Response Plan

The first episode requires immediate discontinuation of medication and medical attention. If diagnosed with drug-related epilepsy, treatment with enzalutamide should be permanently terminated.

Key points of fatigue management

1. Characteristics of occurrence

About 30% of patients experience fatigue symptoms, usually mild to moderate, which often occur in the early stages of treatment and may alleviate over time with medication.

2. Life adjustment

It is recommended to engage in activities in different time periods, maintain moderate exercise, and avoid prolonged bed rest. Pay attention to nutritional supplementation and water intake.

3. Medical intervention

Continuous severe fatigue requires assessment of anemia or thyroid dysfunction, and dose adjustment may be considered if necessary.

Drug interaction management

1. CYP2C8 substrate drugs

Enzalutamide is a potent CYP2C8 inducer that can reduce the concentration of drugs such as repaglinide and pioglitazone, and its efficacy needs to be monitored.

2. Hormonal drugs

Significantly reduce the concentration of prednisone, contraceptive pills, etc. Contraception requires non hormonal methods, and the dosage of glucocorticoids may need to be increased.

3. Anticoagulant drugs

The impact on warfarin metabolism requires an increase in INR monitoring frequency. Caution should also be exercised when using new oral anticoagulants in combination.

Note: The specific medication plan should be formulated by the attending physician based on individual circumstances. This article is for reference only and is not intended as a basis for diagnosis and treatment.